Venkateshwar Chinthalapally
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonic Neoplasms | 5 | 2022 | 117 | 0.890 |
Why?
|
| Adenocarcinoma | 3 | 2022 | 284 | 0.700 |
Why?
|
| Genomic Instability | 4 | 2022 | 33 | 0.660 |
Why?
|
| Mouth Neoplasms | 1 | 2018 | 52 | 0.570 |
Why?
|
| N-Acetylglucosaminyltransferases | 2 | 2016 | 15 | 0.540 |
Why?
|
| Anticarcinogenic Agents | 3 | 2013 | 15 | 0.540 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 152 | 0.530 |
Why?
|
| Apoptosis | 5 | 2015 | 737 | 0.480 |
Why?
|
| Pancreatic Neoplasms | 3 | 2016 | 505 | 0.460 |
Why?
|
| Liver Neoplasms | 2 | 2016 | 164 | 0.460 |
Why?
|
| Isothiocyanates | 1 | 2013 | 11 | 0.440 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 110 | 0.420 |
Why?
|
| Diet | 2 | 2013 | 222 | 0.410 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2014 | 125 | 0.400 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 139 | 0.400 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2015 | 114 | 0.390 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 133 | 0.360 |
Why?
|
| Animals | 16 | 2018 | 9954 | 0.360 |
Why?
|
| Neoplasms | 3 | 2016 | 756 | 0.350 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2016 | 60 | 0.350 |
Why?
|
| Signal Transduction | 4 | 2018 | 1339 | 0.340 |
Why?
|
| Mice | 11 | 2018 | 4402 | 0.320 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 123 | 0.310 |
Why?
|
| Aspirin | 2 | 2012 | 119 | 0.310 |
Why?
|
| Adenomatous Polyposis Coli | 3 | 2013 | 9 | 0.310 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 441 | 0.300 |
Why?
|
| Genes, APC | 3 | 2015 | 14 | 0.290 |
Why?
|
| Chromosomal Instability | 2 | 2015 | 20 | 0.290 |
Why?
|
| Mitosis | 3 | 2015 | 109 | 0.280 |
Why?
|
| Lipoxygenase | 1 | 2007 | 2 | 0.280 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 7 | 0.280 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2007 | 22 | 0.280 |
Why?
|
| Mucins | 1 | 2016 | 22 | 0.280 |
Why?
|
| Cell Cycle Proteins | 3 | 2015 | 184 | 0.280 |
Why?
|
| Mutation | 3 | 2016 | 820 | 0.280 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 656 | 0.270 |
Why?
|
| Chromosome Segregation | 2 | 2009 | 55 | 0.270 |
Why?
|
| Adenoma | 2 | 2013 | 59 | 0.260 |
Why?
|
| Curcumin | 1 | 2007 | 67 | 0.260 |
Why?
|
| Mucin-1 | 1 | 2016 | 35 | 0.260 |
Why?
|
| Eflornithine | 1 | 2014 | 3 | 0.240 |
Why?
|
| Ornithine Decarboxylase | 1 | 2014 | 8 | 0.240 |
Why?
|
| Drug Delivery Systems | 2 | 2016 | 216 | 0.240 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2013 | 8 | 0.230 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2013 | 5 | 0.230 |
Why?
|
| Estrogen Antagonists | 1 | 2013 | 16 | 0.220 |
Why?
|
| Escin | 1 | 2013 | 1 | 0.220 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2013 | 7 | 0.220 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2013 | 9 | 0.220 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 130 | 0.220 |
Why?
|
| rho-Associated Kinases | 1 | 2013 | 12 | 0.220 |
Why?
|
| Antimitotic Agents | 1 | 2012 | 5 | 0.210 |
Why?
|
| Humans | 15 | 2022 | 26856 | 0.210 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 52 | 0.200 |
Why?
|
| Carcinoma in Situ | 1 | 2012 | 44 | 0.200 |
Why?
|
| Plant Extracts | 2 | 2018 | 62 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2012 | 98 | 0.200 |
Why?
|
| Biological Products | 1 | 2012 | 60 | 0.200 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2015 | 129 | 0.200 |
Why?
|
| Azoxymethane | 4 | 2015 | 17 | 0.180 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 339 | 0.170 |
Why?
|
| Intestinal Neoplasms | 2 | 2015 | 15 | 0.160 |
Why?
|
| Microtubules | 1 | 2009 | 89 | 0.160 |
Why?
|
| Carcinogenesis | 2 | 2013 | 79 | 0.150 |
Why?
|
| Momordica charantia | 1 | 2018 | 1 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 5 | 2015 | 1474 | 0.150 |
Why?
|
| Pyrimidines | 1 | 2008 | 121 | 0.150 |
Why?
|
| Immunoenzyme Techniques | 3 | 2015 | 65 | 0.150 |
Why?
|
| Disease Progression | 3 | 2014 | 450 | 0.150 |
Why?
|
| Female | 8 | 2015 | 14462 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 323 | 0.140 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 1259 | 0.140 |
Why?
|
| Acetates | 1 | 2006 | 44 | 0.130 |
Why?
|
| Blotting, Western | 3 | 2015 | 503 | 0.130 |
Why?
|
| Indoles | 1 | 2006 | 98 | 0.130 |
Why?
|
| Mice, Transgenic | 3 | 2015 | 487 | 0.120 |
Why?
|
| Sea Cucumbers | 1 | 2015 | 1 | 0.120 |
Why?
|
| RNA, Messenger | 3 | 2015 | 645 | 0.120 |
Why?
|
| Complex Mixtures | 1 | 2015 | 12 | 0.120 |
Why?
|
| Tissue Array Analysis | 2 | 2016 | 24 | 0.120 |
Why?
|
| Protein Kinases | 1 | 2005 | 143 | 0.110 |
Why?
|
| Rats, Inbred F344 | 3 | 2013 | 167 | 0.110 |
Why?
|
| Cyclooxygenase 2 | 3 | 2013 | 68 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 2 | 2014 | 310 | 0.110 |
Why?
|
| Aberrant Crypt Foci | 1 | 2013 | 2 | 0.110 |
Why?
|
| alpha-Linolenic Acid | 1 | 2013 | 4 | 0.110 |
Why?
|
| Immunity, Innate | 1 | 2015 | 204 | 0.110 |
Why?
|
| Organ Specificity | 1 | 2022 | 81 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 37 | 0.100 |
Why?
|
| Carcinogens | 2 | 2015 | 37 | 0.090 |
Why?
|
| Transcriptome | 1 | 2022 | 198 | 0.090 |
Why?
|
| Rats | 3 | 2013 | 1536 | 0.090 |
Why?
|
| Male | 6 | 2015 | 12866 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2012 | 38 | 0.080 |
Why?
|
| Lung | 1 | 2022 | 346 | 0.080 |
Why?
|
| beta Catenin | 2 | 2012 | 62 | 0.080 |
Why?
|
| Cell Proliferation | 2 | 2015 | 770 | 0.070 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2007 | 16 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2007 | 25 | 0.070 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2007 | 46 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2007 | 86 | 0.070 |
Why?
|
| Polysaccharides | 1 | 2016 | 61 | 0.070 |
Why?
|
| Molecular Structure | 1 | 2007 | 239 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 247 | 0.060 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 144 | 0.060 |
Why?
|
| Glutamate-Ammonia Ligase | 1 | 2015 | 2 | 0.060 |
Why?
|
| Glypicans | 1 | 2015 | 3 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2016 | 277 | 0.060 |
Why?
|
| alpha-Fetoproteins | 1 | 2015 | 18 | 0.060 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 28 | 0.060 |
Why?
|
| Haploinsufficiency | 1 | 2015 | 8 | 0.060 |
Why?
|
| Transfection | 1 | 2016 | 312 | 0.060 |
Why?
|
| Hepatitis B virus | 1 | 2015 | 16 | 0.060 |
Why?
|
| Ornithine Decarboxylase Inhibitors | 1 | 2014 | 2 | 0.060 |
Why?
|
| Hepacivirus | 1 | 2015 | 46 | 0.060 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2015 | 43 | 0.060 |
Why?
|
| HeLa Cells | 1 | 2015 | 206 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 588 | 0.060 |
Why?
|
| Models, Biological | 1 | 2007 | 446 | 0.060 |
Why?
|
| Retinoid X Receptors | 1 | 2013 | 24 | 0.060 |
Why?
|
| Nitrosamines | 1 | 2013 | 5 | 0.060 |
Why?
|
| DNA Damage | 1 | 2015 | 147 | 0.060 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2013 | 18 | 0.060 |
Why?
|
| Retinal Dehydrogenase | 1 | 2013 | 9 | 0.060 |
Why?
|
| Estrogen Receptor beta | 1 | 2013 | 13 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 250 | 0.060 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 88 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 104 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 203 | 0.050 |
Why?
|
| Tobacco | 1 | 2013 | 86 | 0.050 |
Why?
|
| Chemoprevention | 1 | 2012 | 29 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2012 | 19 | 0.050 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2012 | 18 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2012 | 38 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2013 | 282 | 0.050 |
Why?
|
| Integrases | 1 | 2012 | 39 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2015 | 969 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 68 | 0.050 |
Why?
|
| Body Weight | 1 | 2012 | 245 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 377 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 443 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2009 | 2 | 0.040 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2009 | 4 | 0.040 |
Why?
|
| Mad2 Proteins | 1 | 2009 | 10 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2009 | 60 | 0.040 |
Why?
|
| Spindle Apparatus | 1 | 2009 | 52 | 0.040 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 18 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2009 | 69 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2008 | 56 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 29 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2008 | 22 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2009 | 114 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 122 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 245 | 0.040 |
Why?
|
| Dinoprostone | 1 | 2006 | 41 | 0.030 |
Why?
|
| Macrophages, Peritoneal | 1 | 2015 | 10 | 0.030 |
Why?
|
| Oxidoreductases Acting on Sulfur Group Donors | 1 | 2015 | 5 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2005 | 58 | 0.030 |
Why?
|
| Colonic Polyps | 1 | 2005 | 17 | 0.030 |
Why?
|
| Oxidoreductases | 1 | 2015 | 56 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2015 | 78 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 144 | 0.030 |
Why?
|
| Aged | 1 | 2013 | 5169 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 1394 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 152 | 0.030 |
Why?
|
| Gene Expression | 1 | 2005 | 405 | 0.030 |
Why?
|
| Corn Oil | 1 | 2013 | 1 | 0.030 |
Why?
|
| Cyclooxygenase 1 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Plant Oils | 1 | 2013 | 9 | 0.030 |
Why?
|
| Cytokines | 1 | 2015 | 437 | 0.030 |
Why?
|
| Middle Aged | 1 | 2013 | 6825 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2013 | 186 | 0.020 |
Why?
|
| Adult | 1 | 2013 | 7389 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2013 | 466 | 0.020 |
Why?
|